Oxitec Limited: Private Company Information - Businessweek

June 12, 2016 10:09 AM ET

Biotechnology

Company Overview

Oxitec Ltd. operates as a biotechnology company that provides solutions for controlling insects that spread diseases and damage crops. It offers Aedes aegypti OX513A, a bisex RIDL strain for genetic backgrounds in Asia and Latin America; Aedes aegypti OX3604C, a female-flightless RIDL strain for genetic backgrounds in Mexico; Aedes albopictus OX3688, a female-flightless RIDL strain for genetic backgrounds in Asia; Oxitec Diamondback Moth OX4319L, a fluorescent marker to identify the Oxitec moths and distinguish them from wild ones; and Pink bollworm OX1138, a fluorescent marker that glows red when viewed under certain filters. The company also provides Pink bollworm OX3402, a fluorescent mar...

Oxitec Ltd. operates as a biotechnology company that provides solutions for controlling insects that spread diseases and damage crops. It offers Aedes aegypti OX513A, a bisex RIDL strain for genetic backgrounds in Asia and Latin America; Aedes aegypti OX3604C, a female-flightless RIDL strain for genetic backgrounds in Mexico; Aedes albopictus OX3688, a female-flightless RIDL strain for genetic backgrounds in Asia; Oxitec Diamondback Moth OX4319L, a fluorescent marker to identify the Oxitec moths and distinguish them from wild ones; and Pink bollworm OX1138, a fluorescent marker that glows red when viewed under certain filters. The company also provides Pink bollworm OX3402, a fluorescent marker that offers a replacement to irradiation for sterilization of the moths; and Medfly OX3864A, a female-specific strain, which enables separation of the sexes to allow male release by removal of the supplement from the diet of the final release generation. In addition, it offers Mexfly OX3097B, a female specific Oxitec strain that provides female lethality in the absence of a dietary supplement by permitting a male-only release in the final release generation; and Olive fly OX3713A, a female-specific Oxitec strain, which provides separation of the sexes to allow a male release. Oxitec Ltd. was founded in 2002 and is based in Oxford, United Kingdom. As of September 8, 2015, Oxitec Ltd. operates as a subsidiary of Intrexon Corporation.

71 Innovation Drive

Milton Park

Milton

Abingdon,  OX14 4RQ

United Kingdom

Founded in 2002

Key Executives for Oxitec Limited

Chief Executive Officer and Director

Head of Agricultural Research

Head of Public Health Research

Compensation as of Fiscal Year 2015.

Oxitec Limited Key Developments

National Health Surveillance Agency of Brazil (Anvisa) to Grant Special Temporary Registration for Oxitec's GE Mosquito

Apr 13 16

The National Health Surveillance Agency of Brazil (Anvisa) announced that they would grant a special temporary registration (RET, Registro Especial Temporário) to Oxitec to deploy its genetically engineered mosquito, OX513A, known as Friendly Aedes aegypti, throughout the country. Oxitec's biological approach to control the spread of the Aedes aegypti mosquito, the primary vector for transmitting dengue, Zika and chikungunya viruses to humans, was approved by National Technical Biosafety Commission (CTNBio) in 2014. However at that time, Anvisa did not yet have legislation in place to regulate this innovative class of vector control technology. With the guidance issued, Anvisa is elaborating new rules to provide Brazil with a regulatory framework that is able to deal with this and any similar products that may be developed. In the interim Anvisa will grant Oxitec the freedom to use Friendly Aedes aegypti in projects across the country. This should assist the development of the product within Brazil so that it can be used as part of programs designed to fight Aedes aegypti, the dangerous vector of dengue, chikungunya and Zika. Recently recommended by the World Health Organization (WHO) for deployment in operational conditions, the Pan American Health Organization (PAHO) also just declared it will provide technical support for countries that wish to implement OX513A, Oxitec's Friendly Aedes aegypti in the fight against this menacing mosquito. In five separate efficacy trials across Brazil, Panama, and the Cayman Islands, releases of Friendly Aedesaegypti were able to reduce the local populations of wild Aedes aegypti by over 90% in each of the targeted areas. In Piracicaba, Brazil, preliminary results have shown a reduction of 82% in Aedes aegypti wild larvae in the area treated with Friendly Aedes aegypti, compared to the non-treated area.

FDA Publishes Preliminary Finding of No Significant Impact on Oxitec's Self-Limiting Mosquito

Mar 11 16

The US Food and Drug Administration's Center for Veterinary Medicine (FDA-CVM) released in the Federal Register a preliminary finding of no significant impact (FONSI) on Oxitec's self-limiting OX513A Aedes aegypti mosquito for an investigational trial in the Florida Keys. The finding agrees with the draft environmental assessment (EA) submitted by Oxitec Ltd., that concludes a field trial of the Company's genetically engineered (GE) OX513A mosquitoes in Key Haven, Florida, will not result in a significant impact on the environment. This follows an FDA-led evaluation of potential impacts on health and the environment of the proposed trial. The purpose of the proposed trial is to determine the efficacy of Oxitec's self-limiting mosquitoes for the control of the local population of Aedes aegypti in Key Haven, Monroe County, Florida. Oxitec's self-limiting mosquitoes have been genetically engineered so that their offspring die before reaching adulthood. Male Oxitec mosquitoes, which do not bite or spread disease, are released to mate with wild female Aedes aegypti so that their offspring die, reducing the population. Efficacy trials in Brazil, Panama, and the Cayman Islands have tested this approach, and in these trials the population of Aedes aegypti was reduced by more than 90% - an exceptional level of control compared to conventional methods, such as insecticides.

Oxitec Ltd. Presents at BVCA Summit 2015, Oct-08-2015 04:10 PM

Sep 23 15

Oxitec Ltd. Presents at BVCA Summit 2015, Oct-08-2015 04:10 PM. Venue: London, United Kingdom. Speakers: Haydn Parry, Chief Executive Officer.

Similar Private Companies By Industry

Recent Private Companies Transactions